Olaparib (O) in patients (pts) with colorectal cancer (CRC) with ATM mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.

被引：0
|
作者：
Behl, Deepti
Rothe, Michael
Mangat, Pam K.
Garrett-Mayer, Elizabeth
Farrington, Laura Catherine
Crysler, Oxana V.
Dib, Elie G.
Duvivier, Herbert Leon
Hall, Michael J.
Salmon, John Stuart
Alese, Olatunji B.
Marr, Alissa S.
Ngirailemesang, Isa
Polavaram, Latha
Thota, Ramya
Yang, Eddy Shih-Hsin
O'Lone, Raegan
Grantham, Gina N.
Halabi, Susan
Schilsky, Richard L.
机构：
[1] Sutter Sacramento Med Ctr, Sacramento, CA USA
[2] Amer Soc Clin Oncol, Alexandria, VA USA
[3] Canc Treatment Ctr Amer Chicago, Zion, IL USA
[4] Univ Michigan, Rogel Comprehens Canc Ctr, Ann Arbor, MI USA
[5] Michigan Canc Res Consortium, Ypsilanti, MI USA
[6] Canc Treatment Ctr Amer Atlanta, Newnan, GA USA
[7] Fox Chase Canc Ctr, Philadelphia, PA USA
[8] Atrium Hlth, Levine Canc Inst, Charlotte, NC USA
[9] Emory Univ, Winship Canc Inst, Atlanta, GA USA
[10] Univ Nebraska Med Ctr, Omaha, NE USA
[11] Providence Canc Inst, Portland, OR USA
[12] Canc Res Consortium West Michigan, Grand Rapids, MI USA
[13] Intermt Healthcare, Murray, UT USA
[14] Univ Alabama Birmingham, Sch Med, Dept Radiat Oncol, ONeal Comprehens Canc Ctr, Birmingham, AL USA
[15] Duke Univ, Med Ctr, Durham, NC USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
122
引用
收藏
页码：122 / 122
页数：1
相关论文
共 50 条
  • [21] Pertuzumab plus trastuzumab (P plus T) in patients (pts) with lung cancer (LC) with ERBB2 mutation (mut) or amplification (amp): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study
    Ganti, A. K.
    Rothe, M.
    Mangat, P. K.
    Garrett-Mayer, E.
    Dib, E. G.
    Duvivier, H.
    Ahn, E.
    Behl, D.
    Borghaei, H.
    Balmanoukian, A. S.
    Gaba, A.
    Li, R.
    Osei-Boateng, K.
    Thota, R.
    O'Lone, R.
    Grantham, G. N.
    Halabi, S.
    Schilsky, R. L.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S997 - S998
  • [22] Afatinib in patients (pts) with solid tumors with neuregulin 1 (NRG1) fusions: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.
    Ahnert, Jordi Rodon
    Rothe, Michael
    Mangat, Pam K.
    Garrett-Mayer, Elizabeth
    Cannon, Timothy Lewis
    Hobbs, Evthokia
    Kalemkerian, Gregory Peter
    Hinshaw, Dominique C.
    Gregory, Abby
    Grantham, Gina N.
    Halabi, Susan
    Schilsky, Richard L.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [23] Pembrolizumab (P) in patients (pts) with metastatic breast cancer (MBC) with high tumor mutational burden (HTMB): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
    Alva, Ajjai Shivaram
    Mangat, Pam K.
    Garrett-Mayer, Elizabeth
    Halabi, Susan
    Alvarez, Ricardo H.
    Calfa, Carmen Julia
    Khalil, Maged F.
    Ahn, Eugene R.
    Cannon, Timothy Lewis
    Crilley, Pamela A.
    Fisher, Julie Gottlieb
    Haslem, Derrick S.
    Shrestha, Sagun
    Antonelli, Kaitlyn R.
    Butler, Nicole L.
    Warren, Sasha L.
    Rygiel, Andrew Lawrence
    Ranasinghe, Shamika
    Bruinooge, Suanna S.
    Schilsky, Richard L.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [24] Nivolumab Plus Ipilimumab in Patients With Solid Tumors With ATM Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study
    Rohatgi, Nitin
    Rothe, Michael
    Mangat, Pam K.
    Garrett-Mayer, Elizabeth
    Meric-Bernstam, Funda
    Pisick, Evan
    Alese, Olatunji B.
    Reynolds, Christopher M.
    Thota, Ramya
    Vaccaro, Gina M.
    von Mehren, Margaret
    Arend, Rebecca C.
    Chiu, Vi K.
    Duvivier, Herbert L.
    Gold, Philip J.
    Hack, Keely
    Marr, Alissa S.
    Winer, Arthur
    Grantham, Gina N.
    Hinshaw, Dominique C.
    Gregory, Abigail
    Halabi, Susan
    Schilsky, Richard L.
    JCO PRECISION ONCOLOGY, 2023, 7
  • [25] Sunitinib (S) in patients (pts) with metastatic breast cancer (mBC) with FGFR1 mutations or amplifications: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
    Calfa, Carmen
    Rothe, Michael
    Mangat, Pam K.
    Garrett-Mayer, Elizabeth
    Ahn, Eugene
    Gogineni, Keerthi
    Rohatgi, Nitin
    Burness, Monika L.
    Gaba, Anu
    Hamid, Omid
    Albaghdadi, Tareq
    Conlin, Alison
    Gold, Philip
    Rodon, Jordi
    Thota, Ramya
    Schilsky, Richard L.
    CANCER RESEARCH, 2021, 81 (13)
  • [26] Pertuzumab plus trastuzumab (P plus T) in patients (pts) with biliary tract cancer (BTC) with ERBB2/3 amplification (amp), overexpression (oe), or mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.
    Cannon, Timothy Lewis
    Rothe, Michael
    Garrett-Mayer, Elizabeth
    Chiu, Vi Kien
    Hwang, Jimmy J.
    Vijayvergia, Namrata
    Alese, Olatunji B.
    Dib, Elie G.
    Duvivier, Herbert Leon
    Klute, Kelsey
    Sahai, Vaibhav
    Ahn, Eugene R.
    Behl, Deepti
    Sinclair, Sarah
    Thota, Ramya
    Urba, Walter John
    Yang, Eddy Shih-Hsin
    Grantham, Gina N.
    Halabi, Susan
    Schilsky, Richard L.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 546 - 546
  • [27] Sunitinib in Patients with Metastatic Colorectal Cancer (mCRC) with FLT-3 Amplification: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study
    Tareq Al Baghdadi
    Elizabeth Garrett-Mayer
    Susan Halabi
    Pam K. Mangat
    Patricia Rich
    Eugene R. Ahn
    Seungjean Chai
    Andrew L. Rygiel
    Olufunlayo Osayameh
    Kaitlyn R. Antonelli
    Samiha Islam
    Suanna S. Bruinooge
    Richard L. Schilsky
    Targeted Oncology, 2020, 15 : 743 - 750
  • [28] Sunitinib in Patients with Metastatic Colorectal Cancer (mCRC) withFLT-3Amplification: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study
    Al Baghdadi, Tareq
    Garrett-Mayer, Elizabeth
    Halabi, Susan
    Mangat, Pam K.
    Rich, Patricia
    Ahn, Eugene R.
    Chai, Seungjean
    Rygiel, Andrew L.
    Osayameh, Olufunlayo
    Antonelli, Kaitlyn R.
    Islam, Samiha
    Bruinooge, Suanna S.
    Schilsky, Richard L.
    TARGETED ONCOLOGY, 2020, 15 (06) : 743 - 750
  • [29] Palbociclib (P) in patients (pts) with soft tissue sarcoma (STS) with CDK4 amplification: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.
    Schuetze, Scott
    Rothe, Michael
    Mangat, Pam K.
    Garrett-Mayer, Liz
    Meric-Bernstam, Funda
    Farrington, Laura Catherine
    Calfa, Carmen
    D'Andre, Stacy D.
    Livingston, Michael B.
    Thota, Ramya
    Marr, Alissa S.
    von Mehren, Margaret
    Wentzel, Kristopher
    Schilsky, Richard L.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [30] Palbociclib (P) in patients (pts) with non-small cell lung cancer (NSCLC) with CDKN2A alterations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
    Ahn, Eugene R.
    Mangat, Pam K.
    Garrett-Mayer, Elizabeth
    Halabi, Susan
    Dib, Elie G.
    Haggstrom, Daniel Ernest
    Alguire, Kathryn B.
    Alvarez, Ricardo H.
    Calfa, Carmen Julia
    Cannon, Timothy Lewis
    Crilley, Pamela A.
    Gaba, Anu G.
    Marr, Alissa S.
    Sangal, Ashish
    Thota, Ramya
    Antonelli, Kaitlyn R.
    Islam, Samiha
    Rygiel, Andrew Lawrence
    Bruinooge, Suanna S.
    Schilsky, Richard L.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
12345